Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

High-Dose Chemotherapy, Total-Body Irradiation, and Autologous Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Hematologic Cancer or Solid Tumors

7. maj 2013 opdateret af: Roswell Park Cancer Institute

Autologous Blood and Marrow Transplantation for Hematologic Malignancy and Selected Solid Tumors

RATIONALE: Radiation therapy uses high-energy x-rays to damage cancer cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with autologous stem cell transplantation or autologous bone marrow transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells.

PURPOSE: This phase II trial is studying how well eight different high-dose chemotherapy regimens with or without total-body irradiation followed by autologous stem cell transplantation or autologous bone marrow transplantation works in treating patients with hematologic malignancies or solid tumors.

Studieoversigt

Status

Afsluttet

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

OBJECTIVES:

  • Determine the morbidity, mortality, and overall outcome in patients with hematologic malignancies, breast cancer, or other chemosensitive solid tumors treated with disease-specific dose-intensive conditioning regimens and autologous peripheral blood or bone marrow transplantation.

OUTLINE: Patients are stratified according to risk group (standard vs high). Standard risk includes acute leukemia in first relapse or second remission; lymphoma in responding first relapse or second remission; or breast cancer at risk for recurrence. High risk includes all others. Patients receive specific conditioning regimens according to diagnosis as outlined below.

Conditioning

  • Regimen A (standard risk non-Hodgkin's lymphoma and under 60 years of age)-Etoposide, cyclophosphamide, and total body irradiation (TBI) (VCT): Patients receive etoposide IV continuously over 26 hours beginning on day -5 and cyclophosphamide IV over 2 hours on day -4. Patients undergo TBI on days -3 to -1.
  • Regimen B (any risk Hodgkin's lymphoma and under 60 years of age)-Cyclophosphamide, carmustine, and etoposide (CBV): Patients receive etoposide IV continuously over 34 hours beginning on day -8; cyclophosphamide IV over 2 hours on days -7 to -4; and carmustine IV over 2 hours on day -3.
  • Regimen C (any risk patient with prior exposure to high-dose etoposide and cyclophosphamide and under 60 years of age)-Melphalan and TBI (MEL/TBI): Patients receive melphalan IV over 30 minutes on day -4. Patients undergo TBI on days -3 to -1.
  • Regimen D (multiple myeloma or amyloidosis)-Melphalan only (MEL only): Patients receive melphalan IV over 30 minutes on day -2.
  • Regimen E (any patient unable to receive TBI)-Busulfan and cyclophosphamide: Patients receive oral busulfan (or busulfan IV over 2 hours) on days -7 to -4 and cyclophosphamide IV over 2 hours on days -3 and -2.
  • Regimen F (any risk breast cancer)-Cyclophosphamide, carboplatin, and thiotepa (STAMP V): Patients receive cyclophosphamide IV over 24 hours, carboplatin IV over 24 hours, and thiotepa IV over 24 hours on days -7 to -4.
  • Regimen G (solid tumors other than breast or testicular cancer)-Thiotepa and carboplatin (TT/CARBO): Patients receive thiotepa IV over 2 hours on days -6 and -5 and carboplatin IV continuously over 96 hours beginning on day -6.
  • Regimen H (recurrent or primary progressive testicular cancer)-Etoposide and carboplatin (VP/CARBO): Patients receive etoposide IV over 2 hours and carboplatin IV over 30 minutes on days -6 to -4.

Stem Cell Infusion

  • In all regimens, patients undergo autologous stem cell infusion on day 0. Treatment continues in the absence of unacceptable toxicity.

PROJECTED ACCRUAL: Approximately 450 patients (50 patients [25 per stratum] per regimen) will be accrued for this study within 10 years.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

451

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

  • Forenede Stater
    • New York
      • Buffalo, New York, Forenede Stater, 14263-0001
        • Roswell Park Cancer Institute

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

4 år og ældre (Barn, Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

DISEASE CHARACTERISTICS:

  • Histologically confirmed hematologic or solid tumor malignancy, including any of the following:

    • Acute myeloid leukemia

      • First remission and not eligible for allogeneic transplantation; recurrent disease after combination chemotherapy with at least 1 standard regimen; or second remission
      • Not eligible for protocol CLB-9620 or CLB-9621

    • Acute lymphoblastic leukemia

      • First complete remission without appropriate allogeneic donor

    • Chronic myelogenous leukemia

      • Chronic, accelerated, or blast phase

    • Lymphoproliferative diseases*

      • Chronic lymphocytic leukemia
      • Multiple myeloma
      • Waldenstrom's macroglobulinemia
      • Low-grade non-Hodgkin's lymphoma (NHL) NOTE: *Recurrent or persistent, symptomatic disease after first-line chemotherapy, or subsequently

    • Amyloidosis

      • Primary or previously treated disease

    • NHL (intermediate- and high-grade)

      • Resistant or recurrent disease after combination chemotherapy with at least 1 standard regimen

      • First remission lymphoblastic or small, non-cleaved cell lymphoma at high risk of relapse

        • CNS disease OR bone marrow disease and lactic dehydrogenase greater than 300 IU/L

    • Hodgkin's lymphoma

      • Resistant or recurrent disease after combination chemotherapy with at least 1 standard regimen

    • Solid tumors

      • High-risk and metastatic breast cancer
      • Testicular cancer that has relapsed OR primary progressive disease that is responding to salvage therapy
      • Other solid tumors that have recurred after conventional therapy OR are at high risk for relapse, and demonstrate chemosensitivity
  • Less than 10% marrow tumor present histologically (maximum of 15% involvement allowed if purged)

  • Allogeneic marrow transplantation not possible or not desirable for any of the following reasons:

    • Over 60 years of age
    • No compatible donor identified
    • Estimated risk of graft-versus-host disease complications greater than risk of recurrence after autologous bone marrow transplantation
  • Patients with disease progression in a site of prior radiotherapy (4,000 cGy or more) are not eligible for total body irradiation (TBI) regimens

  • Hormone receptor status:

    • Not specified NOTE: A new classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of "indolent" or "aggressive" lymphoma will replace the former terminology of "low", "intermediate", or "high" grade lymphoma. However, this protocol uses the former terminology.

PATIENT CHARACTERISTICS:

Age

  • 4 and over (patients 60 years of age and over are not eligible for TBI)

Sex

  • Male or female

Menopausal status

  • Not specified

Performance status

  • Karnofsky 70-100%

Life expectancy

  • More than 2 months

Hematopoietic

  • WBC greater than 3,000/mm^3*
  • Polymorphonuclear leukocyte count greater than 1,500/mm^3*
  • Platelet count greater than 75,000/mm^3*
  • Marrow cellularity greater than 20%*
  • No marrow fibrosis* NOTE: *Before marrow storage

Hepatic

  • Bilirubin less than 3 times normal
  • Alkaline phosphatase less than 3 times normal
  • AST less than 3 times normal
  • Hepatitis status known

Renal

  • Creatinine clearance at least 50 mL/min (not required for patients with amyloidosis or multiple myeloma)

Cardiovascular

  • Ventricular ejection fraction at least 50% by radionuclide ventriculogram or echocardiogram
  • No myocardial infarction within the past 6 months
  • No congestive heart failure
  • No symptomatic angina
  • No life-threatening arrhythmia or hypertension

Pulmonary

  • DLCO or DLVA at least 50% of predicted (DLCO must be corrected for hemoglobin and/or alveolar ventilation)

Other

  • Not pregnant
  • HIV negative
  • Cytomegalovirus status known
  • No active bacterial, viral, or fungal infection
  • No active peptic ulcer disease
  • No uncontrolled diabetes mellitus
  • No serious organ dysfunction unless it is caused by the underlying disease
  • No other serious medical or psychiatric illness that would preclude giving informed consent or complying with study requirements

PRIOR CONCURRENT THERAPY:

Biologic therapy

  • See Disease Characteristics

Chemotherapy

  • See Disease Characteristics
  • No prior cumulative nitrosourea dose greater than 600 mg/m^2
  • No prior cumulative bleomycin dose greater than 150 units/m^2
  • No prior cumulative doxorubicin dose greater than 450 mg/m^2
  • No prior cumulative daunorubicin dose greater than 600 mg/m^2
  • Patients with prior high-dose cyclophosphamide (greater than 150 mg/kg per cycle) and high-dose etoposide (greater than 2,400 mg/m^2 per cycle) are not eligible for the etoposide/cyclophosphamide/TBI conditioning regimen

Endocrine therapy

  • Not specified

Radiotherapy

  • See Disease Characteristics
  • More than 3 weeks since prior radiotherapy (before blood stem cell harvest)

  • Prior cumulative doses of radiotherapy must not exceed the following:

    • Spine/spinal cord: 4,000 cGy
    • Mediastinum: 4,000 cGy
    • Heart: 4,000 cGy
    • Kidney (whole): 1,500 cGy
    • Small bowel: 4,000 cGy
    • Brain: 4,000 cGy
    • Liver (whole): 2,000 cGy
    • Lungs (whole): 1,500 cGy
    • Bone: 5,000 cGy

Surgery

  • Not specified

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Tidsramme
Morbidity
Tidsramme: +day 100
+day 100
Mortality
Tidsramme: +day 100, +day 360
+day 100, +day 360
Overall outcome
Tidsramme: every 6 months until death
every 6 months until death
Response rate
Tidsramme: +day 100, +day 360
+day 100, +day 360
Toxicity
Tidsramme: +day100, +day 360
+day100, +day 360
Disease-free survival
Tidsramme: up to 15years
up to 15years
Overall survival
Tidsramme: every 6 months until death
every 6 months until death

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Roswell Park Cancer Institute

Efterforskere

  • Studiestol: Philip L. McCarthy, MD, Roswell Park Cancer Institute

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart

1. december 1991

Primær færdiggørelse (Faktiske)

1. august 2006

Studieafslutning (Faktiske)

1. februar 2013

Datoer for studieregistrering

Først indsendt

6. maj 2003

Først indsendt, der opfyldte QC-kriterier

6. maj 2003

Først opslået (Skøn)

7. maj 2003

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Skøn)

9. maj 2013

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

7. maj 2013

Sidst verificeret

1. maj 2013

Mere information

Begreber relateret til denne undersøgelse

Nøgleord

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • CDR0000301587
  • RPCI-DS-9115

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med perifer blodstamcelletransplantation

Søg i lignende forsøg

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

CROs by country

CROs in Kosovo

Betingelser

Sjældne sygdomme

Narkotikainterventioner

Kosttilskud

Sponsor / samarbejdspartnere

Placeringer

Abonner